nutricost bpc 157 BPC-157: Experimental Peptide Creates Risk for Athletes BPC-157 Pro New Protective Compound

Research Use Only (RUO)

The therapeutic use of peptides dates back over a century

Take the first step toward a more rewarding career

Ipamorelin was the first synthetic GHS discovered with a proposed high selectivity towards the growth hormone receptors without apparently affecting the synthesis of other pituitary hormones such as ACTH and prolactin

What Patients Evaluating AOD 9604 Typically Report Timeline to first changes: Most published protocols note 4 to 6 weeks before body composition changes become measurable Areas of change: Visceral and subcutaneous fat reduction, with particular effect reported in the abdominal region in some subjects Energy and recovery: Some participants in clinical and investigational settings report improved energy and exercise recovery, though this is not a primary mechanism of the peptide What it is not: AOD 9604 does not cause rapid dramatic weight loss the way GLP-1 medications can in the first few months